Healthcare / Drug Manufacturers - Specialty & GenericBSE
$7.83
-0.39 (-4.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 12%
FCF escenarios
weak_data · normalized FCF $-497694.00 · quality 27.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$80M
P/E
52.2x
↑EV/EBITDA
104.1x
↑ROE
11.1%
↑Gross Margin
39.3%
↓Debt/Equity
2.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.9%
FCF CAGR
—
FCF margin
3.3%
FCF / Net income
0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.1M · net income $1.0M · FCF $271000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.1M | $8.1M | $10.4M | $8.7M | $4.2M |
| Net Income | $1.0M | $1.0M | $576000.00 | $-404531.00 | $-5.2M |
| EBITDA | $998000.00 | $998000.00 | $602000.00 | $-499934.00 | $-4.5M |
| EPS | 0.10 | 0.10 | 0.06 | -0.04 | -0.50 |
| Gross Margin | 39.3% | 39.3% | 38.2% | 34.4% | 43.2% |
| Operating Margin | 12.2% | 12.2% | 5.1% | -6.4% | -108.5% |
| Net Margin | 12.4% | 12.4% | 5.5% | -4.7% | -124.0% |
| Balance Sheet | |||||
| Debt/Equity | 2.77 | 2.77 | 3.18 | 3.29 | 2.75 |
| Cash Flow | |||||
| Free Cash Flow | $271000.00 | $271000.00 | $-14.1M | $-497694.00 | $-3.5M |
| Returns | |||||
| ROE | 11.1% | 11.1% | 7.2% | -5.4% | -65.8% |
| Valuation | |||||
| P/E | 52.20 | 52.20 | 123.00 | — | — |
| EV/EBITDA | 104.08 | 104.08 | 159.57 | — | — |
| P/B | 8.72 | 8.72 | 8.81 | 7.30 | 6.03 |
| Growth & Yield | |||||
| Revenue Growth | -21.7% | -21.7% | 19.5% | 108.2% | — |
| EPS Growth | 66.7% | 66.7% | 250.0% | 92.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
90.8%
EPS terminal req.
$0.69
Spread vs growth
-24.1%
5Y implied EPS CAGR
53.1%
EPS terminal req.
$0.84
Spread vs growth
13.6%
10Y implied EPS CAGR
29.8%
EPS terminal req.
$1.35
Spread vs growth
36.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.3%
Start / end P/E
148.8x → 78.3x
EPS bridge
0.06 → 0.10
Residual
-31.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.